No Data
No Data
Mizuho Securities Maintains Athira(ATHA.US) With Buy Rating
Mizuho Securities analyst Graig Suvannavejh maintains $Athira(ATHA.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 45.8% and a total average return of -3.9% over
Mizuho Securities Keeps Their Buy Rating on Athira Pharma (ATHA)
Athira (ATHA) Completes Dosing in Alzheimer's Study, Stock Up
Sector Update: Health Care
Health care stocks were mixed late Tuesday afternoon, with the NYSE Health Care Index fractionally lower and the Health Care Select Sector SPDR Fund (XLV) adding 0.4%.The iShares Biotechnology ETF (
Athira Pharma Doses Last Patient Alzheimer's Treatment Study
Athira Pharma (ATHA) said Tuesday it has dosed the last patient in the phase 2/3 for fosgonimeton in patients with mild-to-moderate Alzheimer's disease.The company aims to release top-line results
Express News | Athira Pharma Announces Last Patient Completed Lift-Ad Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
No Data